Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 13Gastrointestinal 6Dermatologic 6Genitourinary 4Sarcoma 3Other neoplasm 3Tumor-Agnostic 1Thoracic 1Lymphoid 1Gynecologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Precancerous Conditions 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Eflornithine × Gynecologic × Clear all
NCT00006079 2018-10-25

Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

M.D. Anderson Cancer Center

Phase 2 Completed
150 enrolled
GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡